Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
ZLAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.01 - $39.77
Previous CloseN/A
Volume273.50K
Average Volume (3M)943.89K
Market Cap
$3.39B
Enterprise Value$3.39B
Total Cash (Recent Filing)$757.26M
Total Debt (Recent Filing)$192.30M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 11, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding110,328,380
10 Day Avg. Volume809,019
30 Day Avg. Volume943,889
Financial Highlights & Ratios
PEG Ratio-4.02
Price to Book (P/B)4.81
Price to Sales (P/S)0.00
P/FCF Ratio-16.56
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue2.27
Enterprise Value/Gross Profit12.77
Enterprise Value/Ebitda-3.08
Forecast
1Y Price Target
$48.40Price Target Upside32.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Zai Lab News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceZai Lab delivered revenue of US$106.5mn, representing YoY growth of 22%.
Product DevelopmentZLAB highlighted recent progress for both global and regional programs, including the initiation of a global Phase I/II study for ZL-1310 in neuroendocrine tumors.
Revenue GrowthZLAB noted that the patient volumes have rebounded, and the company anticipates a return to strong sequential growth throughout the rest of the year.
Bears Say
Competitive PressuresThe presence of more competitors in Zai Lab's core product market offsets the potential benefits of its products nearing commercialization.
Product RevenueProduct revenues for 1Q25 of $105.7M were below the company-provided consensus estimate of $113.9M and were down ~2.6% QoQ from $108.5M in 4Q24.
Safety ConcernsThere has been an increase in Grade 3+ cytopenias (7-21%), new instances of Grade 3+ interstitial lung disease (ILD, 7%), and a rise in treatment discontinuations (18%).
Ownership Overview
1.31% Insiders
20.26% Mutual Funds
23.14% Other Institutional Investors
54.46% Public Companies and Individual Investors
ZLAB FAQ
What was Zai Lab’s price range in the past 12 months?
Zai Lab lowest stock price was $16.01 and its highest was $39.77 in the past 12 months.
What is Zai Lab’s market cap?
Zai Lab’s market cap is $3.39B.
When is Zai Lab’s upcoming earnings report date?
Zai Lab’s upcoming earnings report date is Aug 11, 2025 which is in 66 days.
How were Zai Lab’s earnings last quarter?
Zai Lab released its earnings results on May 08, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.554 by $0.514.
Is Zai Lab overvalued?
According to Wall Street analysts Zai Lab’s price is currently Undervalued.
Does Zai Lab pay dividends?
Zai Lab does not currently pay dividends.
What is Zai Lab’s EPS estimate?
Zai Lab’s EPS estimate is -0.42.
How many shares outstanding does Zai Lab have?
Zai Lab has 110,328,380 shares outstanding.
What happened to Zai Lab’s price movement after its last earnings report?
Zai Lab reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.554. Following the earnings report the stock price went up 2.75%.
Which hedge fund is a major shareholder of Zai Lab?
Currently, no hedge funds are holding shares in ZLAB
Zai Lab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.40 (32.46% Upside)
$48.40 (32.46% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 558.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $714.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.03%
12-Months-Change
Fundamentals
Return on Equity
-32.05%
Trailing 12-Months
Asset Growth
18.71%
Trailing 12-Months
Company Description
Zai Lab
Zai Lab (ZLAB) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company primarily operates in the sectors of oncology, autoimmune disorders, and infectious diseases. Zai Lab builds a portfolio of proprietary and in-licensed drug candidates, aiming to address major unmet medical needs by introducing cutting-edge therapies to patients in China and globally.
ZLAB Company Deck
ZLAB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with strong revenue growth and promising pipeline developments. While there were some temporary challenges such as seasonal declines and inventory dynamics affecting VYVGART sales, the company remains optimistic about achieving its full-year targets.Read More>ZLAB Stock 12 Month Forecast
Average Price Target
$48.40
▲(32.46%Upside)
Technical Analysis
Option Care Health
―
PTC Therapeutics
―
Elanco Animal Health
―
Avidity Biosciences
―
Sotera Health
―